EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Long‐Term Safety and Clinical Outcomes With Olipudase Alfa Enzyme Replacement Therapy in Children and Adolescents With Acid Sphingomyelinase Deficiency

Maurizio Scarpa, George A Diaz, Roberto Giugliani, Simon A Jones, Eugen Mengel, Nathalie Guffon, Peter Witters, Jaya Ganesh, Nicole M Armstrong, Shruti Srivastava, Yong Kim

Journal of Inherited Metabolic Disease · 2025

DOI: 10.1002/jimd.70086 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Maurizio Scarpa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Regional Coordinating Centre for Rare Diseases, University Hospital of Udine, Udine, Italy. Hauptthemen laut MEDLINE: Enzyme Replacement Therapy, Niemann-Pick Disease, Type A, Sphingomyelin Phosphodiesterase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acid sphingomyelinase deficiency (ASMD) is a rare lysosomal storage disease characterized by hepatosplenomegaly, pulmonary dysfunction, dyslipidemia, and growth deficits. Olipudase alfa (recombinant‐human ASM) is the only treatment for non‐central‐nervous‐system ASMD manifestations in children and adults. An open‐label long‐term study followed 4 to 8 years of olipudase alfa treatment in 20 children and adolescents with ASMD (baseline age (years) 1.5–17.5). At final assessments, splenomegaly and hepatomegaly were reduced relative to baseline (mean percent decrease in spleen and liver volumes 78% ± 1.2% and 59.8% ± 1.5%, respectively). Baseline splenomegaly was severe (spleen volume > 15 MN [multiples of normal]) or moderate (5–15 MN) ( n = 12 and n = 8, respectively) versus mild/absent (< 5 MN) ( n = 12) or moderate ( n = 8) at final assessment. Baseline hepatomegaly was severe (liver volume > 2.5 MN) ( n = 10) or moderate (1.25–2.5 MN) ( n = 10) versus mild/absent (< 1.25 MN) ( n = 19) or moderate ( n = 1) at final assessment. Among nine individuals able to perform assessments, diffusing capacity of the lung for carbon monoxide (DL CO ) impairment was severe (< 40%) ( n = 1), moderate (40%–60%) ( n = 4), or mild (60%–80%) ( n = 4) at baseline versus absent ( n = 4), mild ( n = 4) or moderate ( n = 1) at final assessment. Mean percent increase in DL CO was 53.7% ± 6.5%. At baseline, 10/20 children had clinical short stature (height Z ‐scores ≤ − 2) at baseline versus 0/20 at the final assessment. Atherogenic lipid profiles and liver function tests normalized within 2 years and remained stable. Adverse events were mostly mild or moderate, with 4 individuals experiencing 7 serious adverse events, all recovered/resolved. Interpretation: Enzyme replacement therapy with olipudase alfa in children and adolescents with chronic ASMD was well‐tolerated with clinically meaningful improvements in multiple disease parameters. Trial Registration: NCT02004704.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enzyme Replacement TherapyNiemann-Pick Disease, Type ASphingomyelin PhosphodiesteraseAdolescentChildChild, PreschoolFemaleHumansInfantMaleHepatomegalyLiverRecombinant ProteinsSplenomegalyTreatment Outcome

Stichwörter der Autor:innen

Niemann‐Pick type A/BNiemann‐Pick type Bchronic acid sphingomyelinase deficiencydose escalationlung diffusing capacityorganomegalyrecombinant human acid sphingomyelinase

Substanzen

olipudase alfaRecombinant ProteinsSphingomyelin Phosphodiesterase

Autor:innen und Institutionen

  • Regional Coordinating Centre for Rare Diseases, University Hospital of Udine, Udine, Italy.
  • Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Medical Genetics Service HCPA, Department of Genetics UFRGS, INAGEMP, DASA Genomica and Casa dos Raros, Porto Alegre, Brazil.
  • Genomic Medicine, Manchester University National Health Service Foundation Trust, Manchester, UK.
  • SphinCS GmbH, Institute of Clinical Science for Lysosomal Storage Disorders, Mainz, Germany.
  • Reference Centre of Inherited Metabolic Disease in Femme Mère Enfant Hospital, Hospices Civils of Lyon, Lyon, France.

Förderung

  • Sanofi

Zitieren

APA

Scarpa, M., Diaz, G. A., Giugliani, R., Jones, S. A., Mengel, E., Guffon, N., Witters, P., Ganesh, J., Armstrong, N. M., Srivastava, S., & Kim, Y. (2025). Long‐Term Safety and Clinical Outcomes With Olipudase Alfa Enzyme Replacement Therapy in Children and Adolescents With Acid Sphingomyelinase Deficiency. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70086

Vancouver

Scarpa M, Diaz GA, Giugliani R, Jones SA, Mengel E, Guffon N, et al. Long‐Term Safety and Clinical Outcomes With Olipudase Alfa Enzyme Replacement Therapy in Children and Adolescents With Acid Sphingomyelinase Deficiency. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.70086

BibTeX
@article{Scarpa2025,
  author = {Scarpa, Maurizio and Diaz, George A and Giugliani, Roberto and Jones, Simon A and Mengel, Eugen and Guffon, Nathalie and Witters, Peter and Ganesh, Jaya and Armstrong, Nicole M and Srivastava, Shruti and Kim, Yong},
  title = {Long‐Term Safety and Clinical Outcomes With Olipudase Alfa Enzyme Replacement Therapy in Children and Adolescents With Acid Sphingomyelinase Deficiency},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  doi = {10.1002/jimd.70086}
}
Kostenlos starten →